Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Astragaloside IV reduces mutant Ataxin-3 levels and supports mitochondrial function in Spinocerebellar Ataxia Type 3.

Scientific reports - 29 Oct 2024

Lin Yongshiou, Cheng Wenling, Chang Juichih, Wu Yuling, Hsieh Mingli, Liu Chinsan

Abstract excerpt

This study investigated the therapeutic effects of astragaloside IV (AST) on spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), a neurodegenerative disorder. Human neuroblastoma SK-N-SH cells expressing mutant ataxin-3 protein with 78 CAG repeats (MJD78) were employed as an in vitro model. Protein expression analysis demonstrated that AST treatment reduced mutant ataxin-3 protein...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antioxidants
Share to Ataxin-3
Share to Autophagy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Machado-Joseph Disease

Share to Membrane Potential, Mitochondrial

Share to Mitochondrial Dynamics

Share to Saponins

Share to Triterpenes

Source

Open in PubMed Open full text

Identifiers

PMID: 39472629
DOI: 10.1038/s41598-024-77763-2
PMCID: PMC11522510

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Astragaloside IV reduces mutant Ataxin-3 levels and supports mitochondrial function in Spinocerebellar Ataxia Type 3.PMID 39472629Read ↗

Astragaloside IV Reduces Mutant Ataxin-3 Levels and Supports Mitochondrial Function in Spinocerebellar Ataxia Type 3Semantic proximity Read ↗

Machado–Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapySemantic proximity Read ↗

Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to TherapeuticsSemantic proximity Read ↗

n-Butylidenephthalide Modulates Autophagy to Ameliorate Neuropathological Progress of Spinocerebellar Ataxia Type 3 through mTOR Pathway.Semantic proximity Read ↗

Caffeic acid and resveratrol ameliorate cellular damage in cell and Drosophila models of spinocerebellar ataxia type 3 through upregulation of Nrf2 pathway.Semantic proximity Read ↗

Trehalose prevents the formation of aggregates of mutant ataxin-3 and reduces soluble ataxin-3 protein levels in an SCA3 cell model.Semantic proximity Read ↗

Recent therapeutic prospects for Machado–Joseph diseaseSemantic proximity Read ↗

Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado–Joseph Disease through Integration of Pathological Biomarkers and Therapeutic StrategiesSemantic proximity Read ↗

Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.Semantic proximity Read ↗

Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease.Semantic proximity Read ↗

Astragaloside IV alleviates neuronal ferroptosis in ischemic stroke by regulating FTO-m6A-ACSL4 axisSemantic proximity Read ↗

Small Molecules Inducing Autophagic Degradation of Expanded Polyglutamine Protein through Interaction with Both Mutant ATXN3 and LC3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.